In Brief
Receptor-mediated transcytosis is a promising approach for delivering therapeutics across the blood-brain barrier. However, only a limited number of receptors have demonstrated success. Zuchero et al. describe novel receptor pathways that can be exploited for brain transport of antibody drugs.
INTRODUCTION
Delivery of antibody therapeutics into the brain to treat central nervous system (CNS) diseases has been a major drug development challenge. With the support of astrocytes and pericytes, a monolayer of endothelial cells creates the blood-brain barrier (BBB), which serves to restrict movement of substances from the circulating blood to the CNS. Generally, only $0.1% of circulating antibodies cross the intact BBB, severely limiting the therapeutic utility of antibody therapeutics for CNS disorders (Poduslo et al., 1994; Yu and Watts, 2013) .
Many endogenous molecules in circulation are able to cross the BBB via specific receptors and transporters expressed on the luminal side of brain endothelial cells. These membrane protein pathways provide a promising route for delivering antibodies across the BBB by utilizing receptor-mediated transcytosis (RMT) (Fishman et al., 1987; Roberts et al., 1993; Jones and Shusta 2007; Watts and Dennis 2013) . For example, systemic administration of antibodies against the transferrin receptor (TfR), which is highly expressed on BECs, dramatically enhances CNS delivery of these antibodies across the BBB in both rodents and nonhuman primates (Jefferies et al., 1984; Kissel et al., 1998; Yu et al., 2011; Couch et al., 2013; Yu et al., 2014) . However, targeting TfR with antibodies posed safety liabilities (Couch et al., 2013) . Although mitigation strategies could be developed, the identification of additional RMT targets for enhanced brain delivery is warranted. A number of other BBB receptors have been explored for RMT, but their ability to transport therapeutically relevant doses of antibodies into the brain remains to be demonstrated.
In the current study, we generated antibodies against several potential protein targets and tested for their uptake in brain in vivo. We first addressed whether antibodies against previously studied RMT targets could accumulate in brain. We also tested RMT targets identified by differential gene expression analysis via microarray. Finally, an unbiased proteomics approach was used to identify highly expressed transmembrane proteins from isolated mouse primary BECs. Using this approach, three transmembrane BEC proteins were identified as novel candidates for transporting therapeutic antibodies across the BBB.
RESULTS

Receptor-Mediated Transcytosis Evaluation of Lrp1 and InsR
Several murine RMT targets were evaluated for their ability to transport antibodies across the BBB using the screening cascade outlined in Figure 1A . Antibodies that bound specifically to murine antigen as assessed by flow cytometry (FACS) were tested qualitatively for their ability to target mouse brain in vivo by immunostaining mouse cortical tissue 1 hr after a 5 mg/kg dose. Because binding affinity of the antibody to the RMT target can influence brain uptake depending on the dosing paradigm, both a radiolabeled trace dose ($0.1 mg/kg) and a higher therapeutically relevant dose (20 mg/kg) were then used to assess brain uptake of potential RMT antibodies (Yu et al., 2011) . As a final assessment, selected antibodies were engineered as bispecific antibodies containing a monovalent anti-BACE1 arm. This allows a direct demonstration of antibody delivery into the brain by measuring b-amyloid (Ab) concentrations as a function of BACE1 inhibition (Yu et al., 2011) .
We first evaluated two commonly studied RMT targets, lowdensity lipoprotein receptor-related protein 1 (Lrp1) and insulin receptor (InsR), for their ability to deliver antibodies into mouse brains. Antibodies against murine Lrp1 and InsR were generated from naive antibody phage libraries. FACs analysis using HEK293 cells expressing murine Lrp1 or InsR confirmed positive (E) Antibody concentrations in brain 1 and 24 hr after a 20 mg/kg dose of the indicated antibody. Bar graphs represent mean ± SEM (n = 6 per group and time point; *p % 0.05, **p % 0.01, ***p % 0.001, ****p % 0.0001 compared to control IgG at the same time point).
binding ( Figure 1B ). However, these antibodies did not appear to localize to brain vasculature in vivo as assessed by immunostaining of mouse cortical tissue 1 hr after a 5 mg/kg dose (Figure 1C) . As a positive control, an anti-TfR A exhibited pronounced brain vascular distribution following systemic administration (Yu et al., 2011 Couch et al., 2013) .
To Figure 1D ). Using a higher therapeutically relevant dose (20 mg/kg) of anti-Lrp1 did not improve brain accumulation of antibody above that observed for a control IgG, while anti-InsR exhibited a modest increase in brain levels at both time points, but well below anti-TfR A ( Figure 1E ). Together, these results show that of these widely studied receptors, only antibodies against TfR exhibit robust brain uptake.
mRNA Enrichment at the BBB Is Not Sufficient to Identify an RMT Target To identify novel RMT targets, we first took a gene expression analysis approach and reasoned that RMT candidates specifically expressed by BECs could target therapeutics selectively to brain by reducing target-mediated clearance in peripheral organs and improving pharmacokinetics (PK) in vivo. A previous microarray expression profile of FACS-purified mouse brain endothelial cells (Tam et al., 2012) identified two singlepass transmembrane proteins, Ldlrad3 and CD320, each selectively expressed at a higher level by BECs relative to liver and lung endothelial cells (Figure 2A ). Interestingly, Tfrc had higher mRNA expression at the BEC, while Lrp1 and Insr lacked any -labeled antibodies at various time points postdose after intravenous administration in wild-type mice, quantified as mean ± SEM percent injected dose per gram of brain tissue (n = 3 per group and time point). (E and F) Antibody concentrations in brain 1 and 24 hr after a 20 mg/kg dose of the indicated antibody. Data in (E) were obtained concurrently with data in Figure 1E as part of a single experiment; thus the same control IgG and anti-TfR A are shown. Bar graphs represent mean ± SEM (n = 6 per group and time point; *p % 0.05, ****p % 0.0001 compared to control IgG at the same time point).
enhanced BEC expression compared to liver and lung endothelial cells, suggesting some commonly studied RMT targets lack selective enrichment at the BBB. Antibodies against mouse Ldlrad3 and CD320 were generated to investigate whether these selectively expressed receptors could enhance brain uptake. FACs analysis using HEK293 cells expressing murine receptor was used to confirm antigenspecific cell surface binding for both antibodies ( Figure 2B ). Immunostaining of cortical brain tissue 1 hr after a 5 mg/kg dose revealed modest immunoreactivity for anti-Ldlrad3 and a lack of antibody localization for anti-CD320 ( Figure 2C Figure 2D) . (Figure 2C) . We thus employed a proteomics approach to identify transmembrane proteins that are highly expressed in BECs to investigate whether protein levels would better predict potential RMT receptors.
We used FACs to isolate CD31-positive/CD45-negative BECs from wild-type mice as previously described (Tam et al., 2012) ( Figure 3A) . The mass spectrometry analysis of FACs-purified BECs identified established endothelial cell-specific proteins as expected ( Figure 3B ). Peptide counts from the negatively selected non-BEC lysate (i.e., CD31-negative/CD45-negative) revealed an abundance of glial-specific proteins indicating a mixed population of glial cells and neurons . In the BEC population, peptide counts revealed TfR to be the highest single-pass transmembrane protein, while protein levels of Lrp1, InsR, Ldlrad3, and CD320 were all below detection ( Figure 3C ). Interestingly, some peptide counts of Lrp1 were detected in the non-BEC population, which is consistent with previous reports that Lrp1 expression is restricted to neurons, pericytes, and other glial cells (Lillis et al., 2005; Tooyama et. al., 1995; Zhang et al., 2014) . Thus, the poor brain antibody delivery of previously described RMT targets (LRP and InsR) is likely explained by the low abundance of these proteins on BECs.
Importantly, this proteomics analysis revealed several highly abundant transmembrane proteins that have not been previously studied for RMT of antibodies. These include the extracellular matrix metalloproteinase inducer basigin (Bsg), the glucose transporter Glut1, and the solute carrier CD98 heavy chain (CD98hc) ( Figure 3C ). In agreement with our results, a recently published comprehensive RNA-seq transcriptome analysis of distinct cell populations in the mouse brain also reveals high absolute mRNA levels for Tfrc, Bsg, Slc2a1 (Glut1), and Slc3a2 (CD98hc) and very low absolute mRNA levels for Lrp1, Insr, Ldlrad3, and Cd320 on BECs ( Figure 3D ; Zhang et al., 2014) . To test whether high protein levels at the BBB correlates with potentially high transport capacity, we generated antibodies against these abundantly expressed targets and evaluated their RMT potential in vivo.
Evaluation of Antibodies against Highly Expressed BBB Proteins for RMT A total of five distinct antibodies against murine basigin, Glut1, and CD98hc were generated and evaluated: two for anti-Bsg (A and B), one for anti-Glut1, and two for anti-CD98hc (A and B). Binding was confirmed by FACs using HEK293 cells expressing the respective murine antigen ( Figure 4A ). In vivo antibody binding was assessed by immunostaining of cortical tissue 1 hr postdose from wild-type mice IV injected with a 5 mg/kg dose. Pronounced vascular localization was observed with all five antibodies at levels comparable to what was previously observed with anti-TfR A ( Figure 4B , compared to Figure 1C ). A radiolabel trace dose of the higher-affinity I 125 -anti-Bsg A revealed a significant accumulation in brain for the duration of the study, while there was only a modest accumulation in the loweraffinity I 125 -anti-Bsg B compared to I 125 -control IgG ( Figure 4C ). The difference between the two anti-Bsg clones may be due to differences in their binding epitope and/or affinity to Bsg. The latter possibility would be consistent with the affinity-dependent differences previously observed with anti-TfR antibody variants at trace dose levels (Yu et al., 2011) . I 125 -anti-Glut1 also accumulated in brain compared to I
125
-control IgG at all time points postdose ( Figure 4D ). Most strikingly, brain concentrations of both I 125 -anti-CD98hc
A and I 125 -anti-CD98hc B were the highest of the three RMT targets evaluated, with both anti-CD98hc clones reaching brain levels $80-to 90-fold above control IgG and $4-to 5-fold above I 125 -anti-TfR A at their peaks ( Figure 4E , note differences in scale from Figures 4C and 4D ). Other tissue distribution was also examined and we found greater accumulation of anti-CD98hc antibodies in liver and lung compared to control IgG (data not shown).
When wild-type mice were IV injected with a higher therapeutic dose of 20 mg/kg, $2-to 4-fold higher levels of anti-Bsg A and anti-Bsg B were observed in brain at 1 and 24 hr relative to control IgG, comparable to anti-TfR A at both time points (Figures 4F and see Figure S2A available online). In a similar experiment using a 20 mg/kg dose of anti-Glut1, brain concentrations of anti-Glut1 were $1.5-to 3-fold higher than control IgG and comparable to anti-TfR A at both time points (Figures 4G and S2B) .
Of the three RMT candidates, systemic injections of CD98hc antibodies revealed the highest brain concentrations. Brain concentrations of anti-CD98hc
A and anti-CD98hc B were $9-and 11-fold over that of control IgG, respectively, at 24 hr postdose (Figures 4H and S2C) . Furthermore, at 24 hr, brain levels of anti-CD98hc A were significantly higher than that of anti-TfR A . Although all three RMT candidates showed brain uptake by trace and therapeutic dosing, these in vivo studies reveal CD98hc to be the most robust RMT candidate.
To further confirm that dosed antibodies definitively cross the BBB and penetrate parenchyma, we assessed the amount of antibody retained in the parenchyma fraction after microvessel depletion of brain homogenates by ELISA. Dosed antibody was clearly detected for all three targets compared to the control antibody, suggesting there was significant passage of antibody across the BBB which bound to the parenchyma isolates (Figure S2D) . Consistent with trace and therapeutic dose studies, anti-CD98hc antibody in the parenchyma fraction showed the greatest brain concentration ( Figure S2D ). The minimal uptake of anti-Glut1 may be a consequence of the specific expression of Glut1 (Slc2a1) in BECs; the protocol to deplete microvessels may not allow for an accurate quantification of remaining antibody in the parenchymal fraction where no antigen is expressed. Thus, antibodies against CD98hc were selected for further in vivo validation as bispecific antibodies as a result of multiple lines of evidence showing the most robust uptake in brain.
Evaluation of Anti-CD98hc/BACE1
In order to provide a robust CNS pharmacodynamic (PD) readout that would confirm the ability of an antibody to cross the BBB, we generated bispecific antibodies that bind to CD98hc on one arm, and to the amyloid precursor protein (APP) cleavage enzyme b-secretase (BACE1) on the other arm . BACE1 is an enzyme that is considered to be the primary generator of Ab found in plaques in the brains of Alzheimer's disease patients (Vassar et al., 1999) . We previously generated an antibody against BACE1 to inhibit enzymatic activity and thereby reduce Ab production . However, this antibody has poor BBB penetration and was ineffective at reducing brain Ab unless dosed at very high concentrations, or paired with antiTfR as a bispecific antibody Yu et al., 2011) . Both anti-CD98hc
A and anti-CD98hc B were reformatted as bispecific antibodies to allow for a direct assessment of CD98hc-mediated antibody transport across the BBB into the parenchyma through the measurement of brain Ab levels (refer to Figure 1A) . A reduction in CD98hc binding affinity was observed when bivalent anti-CD98hc was converted into a monovalent/bispecific format as measured by competitive ELISA ( Figure 5A ). While the affinity of anti-CD98hc
A was reduced only $2-fold, the affinity of anti-CD98hc B was reduced by $100-fold, indicating that avidity plays an important role in the bivalent binding of this particular antibody. Radiolabel trace dosing revealed significantly higher peak brain uptake at 1 hr postdose of anti-CD98hc A /BACE1 compared to both control IgG and anti-TfR A /BACE1 ( Figure 5B ; p < 0.0001). The lower affinity anti-CD98hc B /BACE1 exhibited increased brain uptake compared to control IgG but was below that of anti-CD98hc A /BACE1, likely due to the substantial reduction in binding affinity to CD98hc as a bispecific antibody (Yu et al., 2011) . To determine extent and duration of anti-CD98hc/BACE1 brain uptake and PD response, a single 50 mg/kg IV injection of either control IgG or anti-CD98hc/BACE1 was administered in wild-type mice. Plasma clearance of the higher affinity antiCD98hc A /BACE1 antibody was much faster compared to the lower affinity anti-CD98hc B /BACE1, as would be expected for a target-mediated clearance mechanism ( Figure 5C ). Both antiCD98hc/BACE1 bispecifics showed significant brain accumulation up to 4 days postdose ( Figure 5D ). Brain concentrations of anti-CD98hc B /BACE1 remained elevated at day 7 postdose, while the concentration of anti-CD98hc A /BACE1 was comparable to control IgG at this later time point. Taken together, the lower affinity anti-CD98hc B /BACE1 produced better peripheral and brain exposure over time compared to the higher affinity anti-CD98hc A / BACE1 ( Figures 5C and 5D) . A similar inverse relationship between antibody affinity and brain exposure was also previously observed for anti-TfR/BACE1 antibodies (Couch et al., 2013) . Importantly, both CD98hc/BACE1 antibodies reduced brain Ab by $30%-45% compared to control IgG-treated mice up to 4 days postdose, demonstrating successful transport of these antibodies into the brain parenchyma ( Figures 5E and 5F) . We also performed in vivo two-photon microscopy to visualize the real-time trafficking of fluorescently labeled CD98hc/ BACE1 bispecific variants within the parenchyma and subcortical vasculature of therapeutically dosed mice ( Figure S3 ). Compared to mice dosed with control IgG and anti-CD98hc B / BACE1, we detected a distinct difference in the vascular clearance of anti-CD98hc A /BACE1, as predicted by the faster plasma PK of the higher affinity variant ( Figure S3 ). In addition, we observed greater diffuse signal in the parenchyma of mice dosed with fluorescently labeled anti-CD98hc B /BACE1
by 48 hr, and to a lesser extent anti-CD98hc A /BACE1, indicating enhanced crossing of the antibody through the BBB.
Antibody Treatments Do Not Alter Endogenous CD98hc Expression and Function
Immunocytochemistry on primary mouse BECs revealed that a majority of CD98hc localized to the plasma membrane with some colocalization with caveolin1-and EEA1-positive puncta ( Figure S4 ). Very few puncta colocalized with TfR, a marker of recycling endosomes. We previously observed that antibodies against TfR drive lysosomal degradation of TfR in an affinitydependent manner, leading to decreased TfR levels both in vitro and in vivo . Thus, we examined the endogenous levels of CD98hc in IMCD3 cells. IMCD3s were used as CD98hc is highly expressed in the kidney tubules, and this cell line also form tight junction barrier with uniform CD98hc expression levels. Cells treated with increasing concentrations of antiCD98hc bispecific antibodies did not change the expression level or stability of CD98hc ( Figures 6A and 6B ). We also examined whether antibody treatment induced changes in the subcellular localization of CD98hc. Consistent with the western blot results, a majority of CD98hc remained on the plasma membrane and with no increased trafficking of CD98hc to Lamp1-positive lysosomes ( Figures 6C and 6D) . Moreover, neither CD98hc bispecific affinity variant affected total brain CD98hc expression in brain lysates from mice that were dosed with 50 mg/kg of anti-CD98hc/ BACE1 between 1 and 7 days ( Figures 6E-6I ). We also evaluated the CD98hc amino acid transport level in the presence or absence of the anti-CD98hc antibodies. As a positive control, we observed transport inhibition by the system-L-specific substrate BCH (2-amino-2-norbornane-carboxylic acid). No inhibition was observed with anti-CD98hc antibody treatments ( Figure 6J ). Taken together, these data indicate that CD98hc is a novel high-capacity RMT pathway capable of delivering antibody therapeutics across the BBB without perturbing CD98hc biology.
DISCUSSION
The idea of utilizing endogenous proteins expressed at the BBB for brain transport of therapeutics into the CNS has been studied for decades (Walus et al., 1996; Boado et al., 2007; Jones and Shusta, 2007; Yu and Watts 2013) . Due to its prominent expression on brain endothelial cells, TfR has been the most studied target (Jefferies et al., 1984; Lee et al., 2000; Jones and Shusta 2007; Yu and Watts 2013) . Although many studies have reported additional RMT pathways for deliver across the BBB, none have shown transport of therapeutically relevant doses of antibody into the brain parenchyma with the exception of antibodies against TfR. Recently we demonstrated antibodies against TfR significantly accumulate in the brain parenchyma when administered systemically in both mice and primates (Yu et al., 2011 Couch et al., 2013) . What remained to be convincingly demonstrated is whether other plasma membrane BEC proteins can be utilized in a similar manner, thus expanding the potential molecular approaches available to enhance large molecule transport across the BBB.
Although Lrp1 and InsR have been explored for RMT across the BBB (Pardridge et al., 1995; Wu et al., 1997; Boado et al., 2007; Karkan et al., 2008; Bertrand et al., 2011) , we were unable to demonstrate appreciable brain uptake of antibodies against these targets. Our mass spectrometry analysis of isolated mouse BECs identified very little detectable signal for these targets, suggesting relatively low abundance at the BBB. Our results are also consistent with the reported low absolute mRNA expression in brain endothelial cells for both Lrp1 and InsR from a recently published quantitative RNA-seq dataset of distinct cell populations in the mouse brain . Low protein abundance was also found for transmembrane targets that were previously identified as being highly enriched by relative mRNA expression in brain endothelial cells, such as Ldlrad3 and CD320. Retrospectively, it was not surprising that we were unable to observe an increase in brain uptake of antibodies against these enriched targets, as their low protein expression does not support a notable enhancement of delivery across the BBB in mice. Thus, using only selective mRNA expression criterion does not predict capacity for brain uptake of antibodies.
We next turned to protein abundance analysis using mass spectrometry of freshly isolated mouse BECs and identified three highly expressed transmembrane proteins: basigin, Glut1, and CD98hc. We demonstrated that antibodies against these highly expressed targets resulted in increased antibody transport into the brain. Thus high protein abundance at the BBB is likely an essential criterion when selecting a RMT target to improve brain uptake of systemically administered antibodies. Because receptor abundance is likely different between human and mouse brain endothelial cells, further confirmation of the targets identified through our mouse studies by proteomics analysis of human brain endothelial cells is necessary. Interestingly, proteomics on human brain microvasculature showed that both CD98hc (4F2hc) and Glut1 are highly expressed (Uchida et al., 2011) , which suggests that both targets hold the potential to translate into human therapeutics.
To our knowledge, this is the first demonstration that CD98hc, the most promising of the three targets identified from our BBB proteomics analysis, is a robust RMT target for transport of large molecules into the brain. CD98hc is a member of the solute carrier family and heterodimerizes with a number of CD98 light chain members to form amino acid transporters at the BBB (Boado et al., 1999) . CD98hc ranked as having the second highest peptide count for a single-pass transmembrane protein identified from our data set (with TfR being the highest). The intracellular portion of CD98hc functions to mediate integrin signaling, which plays a role in both cell growth and tumorigenesis (Feral et al., 2007; Cantor and Ginsberg, 2012) . Our bivalent antibodies against CD98hc exhibited significant increases in brain uptake at both trace and therapeutic dose levels after systemic administration. Importantly, CNS uptake of systemically administered anti-CD98hc A /BACE1 and anti-CD98hc
B /BACE1 is further demonstrated by significant reduction in brain Ab levels. The plasma PK of the two anti-CD98hc/BACE1 clones correlated with their binding affinity to CD98hc, likely due to targetmediated plasma clearance since CD98hc is also expressed in peripheral tissues (Parmacek et al., 1989; Nakamura et al., 1999) . Lowering CD98hc affinity reduces target-mediated clearance, thus increasing peripheral exposure over time and ultimately leading to sustained brain uptake. This inverse relationship between antibody affinity for a BBB target and brain exposure of antibody over time is consistent with previous observations using affinity variants of anti-TfR/BACE1, and further substantiates a general principle of improving brain uptake with a RMT target binding affinity that may be lower than most conventional therapeutic antibodies (Couch et al., 2013) . The optimal affinity range for maximizing brain uptake and exposure for each RMT target likely depends on the therapeutic dose, the duration of the desired effect, and the inherent biology and function of the RMT receptor at the BBB. Based on previous findings with anti-TfR, further reductions in anti-CD98hc affinity may produce even better peripheral PK, resulting in increased brain accumulation (Yu et al., 2011) . Thus, additional affinity variants of anti-CD98hc should be explored to optimize CD98hc-dependent brain transport capacity.
Although we show that antibody treatments did not affect CD98hc localization, stability and biological function (i.e., amino acid transport), the ability to target CD98hc safely with antibodies has yet to be fully investigated. Noteworthy, an antiCD98hc antibody (IGN523) with full effector function has been investigated in a phase I study for patients with acute myeloid leukemia (Igenica Biotherapeutics, Inc.), with no adverse events reported thus far. The possibility of retaining effector function (E-H) Western blot analysis of CD98hc expression in brain lysates after a single 50 mg/kg dose of the indicated antibodies at various days postdose (n = 5 per group and time point). (I) Quantification of CD98hc levels in the western blots. All graphs represent mean ± SEM (n = 5 per group and time point). (J) IMCD3 cells stably overexpressing mouse CD98hc cells were treated with 1 mM of indicated antibodies for 24 hr, and amino acid uptake activity was assessed by the amount total internalized HPG, a methionine analog. BCH (2-amino-2-norbornane-carboxylic acid), an inhibitor of a system L amino acid transporter, was used as a positive control. Methionine uptake was expressed as a percentage of Control IgG and plotted against each data point. Bars represent mean ± SEM (n = 12). See also related Figure S4 .
with anti-CD98hc antibodies could be beneficial for therapeutic targets where Fc gamma receptor activation may play an important role in efficacy (e.g., anti-Ab), which was not possible with anti-TfR antibodies due to high TfR expression on immature red blood cells causing their rapid depletion (Couch et al., 2013) .
In summary, we have identified three promising new RMT targets for enhancing brain uptake of antibody therapeutics. These novel candidates were discovered using an unbiased mass spectrometry-based analysis screening for the most abundantly expressed BEC transmembrane proteins. In particular, we identified CD98hc as a promising novel RMT target that can deliver antibodies across the BBB and produce a robust PD response in the brain, thus broadening the possibilities for developing BBB platforms that can deliver therapeutic antibodies to the brain.
EXPERIMENTAL PROCEDURES
Antibody Generation
The Lrp1 complementary repeat domains 5 and 6 were expressed in E. coli as His-tagged recombinant protein. His-tagged CD320 and CD98hc extracellular domains were expressed in Chinese hamster ovary (CHO) cells, and the extracellular domain of murine Basigin (Bsg) was expressed as murine Fc-tagged protein in CHO cells. These recombinant proteins were then purified on nickel or protein A columns. Recombinant InsR was purchased from R&D system (#1544-IR-050). Recombinant Ldlrad3 was purchased from Novus Biologicals (catalog #H00143458-P01). The anti-Lrp1, anti-InsR, and anti-Ldlrad3 antibodies were selected from human antibody phage libraries. The anti-CD320, anti-Bsg, and anti-CD98hc antibodies were generated using the murine extracellular domains of the corresponding proteins to immunize mice, rats, or hamsters using standard protocols. The anti-Glut1 antibody was generated by DNA immunization in mouse using plasmid coding for the full-length Glut. The hybridomas that were generated were screened by ELISA for antigen binding and by FACs for recognition of the antigen transiently expressed on HEK cells. All antibodies were reformatted as chimeras containing a human Fc for all studies. Affinities are listed in Figure S2E .
Naive Phage Library Sorting A total of 10 mg/mL of the recombinant antigen was coated overnight on NUNC 96-well Maxisorp immunoplates and preblocked with PBST (PBS and 1% bovine serum albumin [BSA] and 0.05% Tween 20). The natural synthetic diversity phage antibody libraries (Lee et al., 2004; Liang et al., 2007) , preblocked with PBST, were subsequently added to the plates and incubated overnight at room temperature (RT). The plates were washed with PBST and bound phage were eluted with 50 mM HCl and 500 mM NaCl for 30 min and neutralized with 1M Tris base. Recovered phage particles were amplified in E. coli XL-1 blue cells. During subsequent selection rounds, the incubation time was reduced to 2-3 hr and the stringency of washing was gradually increased. Unique phage antibodies that bind specifically to the antigen were chosen and reformatted to full length IgGs by cloning VL and VH regions of individual clones into the LPG3 and LPG4 vectors, respectively, and transiently expressed in mammalian CHO cells.
Development of Antibodies against RMT Targets
Balb/c mice (Charles River Laboratories International, Inc., Wilmington, MA, USA), Lewis rats (Charles River, Hollister, CA), or Armenian hamsters (Cytogen, MA) were immunized with purified antigen extracellular domain via footpad or intraperitoneal, at 3-4 days interval in Ribi adjuvant (Sigma) or plasmid DNA encoding the full-length antigen in the presence of GM-CSF diluted in Ringer's solution via hydrodynamic tail vein delivery (HTV), weekly injections. Following 6-12 injections, immune serum titers were evaluated by direct ELISA and FACS binding to transiently transfected HEK293 cells. Splenocytes and/or lymphocytes from animals demonstrating FACS binding were fused with mouse myeloma cells (X63.Ag8.653; American Type Culture Collection, Manassas, VA, USA) by electrofusion (Hybrimmune; Harvard Apparatus, Inc., Holliston, MA, USA). After 10-14 days, hybridoma supernatants were harvested and screened for IgG secretion by direct ELISA or FACS. Final hybridoma clones demonstrating FACS binding were reformatted into human IgG1 or effectorless, kappa backbone. The reformatted antibodies are expressed and supernatants purified by affinity chromatography using MabSelect Sure (GE Healthcare, Piscataway, NJ, USA), eluted in 50 mM phosphoric acid (pH 3.0) plus 20X PBS (pH 11) and stored at 4 C.
FACs Analysis
Purified antibodies were screened on HEK293 cells transfected with the corresponding antigens. Cells were collected from flasks/dishes, washed with phosphate-buffered saline (PBS), and added to 96-well U-bottom plates (BD Falcon 353077) at 1,000,000 cells per well. Samples were added to cells (100 uL/well) and incubated at 4 C for 30-60 min. Plates were then centrifuged
(1,200 rpm, 5 min, 4 C) and washed twice with PBS/1% FBS (200 ul per well).
R-Phycoerythrin-conjugated Ziege anti-human IgG Fc (Jackson ImmunoReseach 109-116-098; 100 ul diluted in PBS) was then added and the plates incubated at 4 C (covered) for 30 min. After the final wash, the cells were fixed in PBS containing 1% formalin and read using a FACSCalibur flow cytometer (BD). Mean fluorescence intensity (MFI) of each sample was then measured using the FlowJo software (Treestar, Inc.).
Competition Enzyme-Linked Immunosorbent Assay
Nunc 96-well Maxisorp immunoplates were coated overnight at 4 C with antigen (2 ug/ml) and blocked for 1 hr at RT with blocking buffer PBST. Serial dilutions of bivalent or bispecific antibodies were subsequently added to the plates with a sub-saturating concentration of biotinylated bispecific antibody at RT for an hour. Plates were washed with wash buffer (PBS with 0.05% Tween 20) and incubated for 30 min with horseradish peroxidase (HRP)-conjugated streptavidin, and developed with tetramethylbenzidine (TMB) substrate. Absorbance was measured spectrophotometrically at 650 nm.
Radiolabel Trace Dosing
Radioiodination All antibodies used in the studies were radioiodinated with iodine-125 ( 125 I) using the indirect iodogen addition method as previously described (Chizzonite et al., 1991) . The radiolabeled proteins were purified using NAP5Ô columns pre-equilibrated in PBS. They were shown to be intact by size-exclusion HPLC. In Vivo Biodistribution in C57BL/6 Female Mice The Institutional Animal Care and Use Committees (IACUC) of Genentech Laboratory Animal Resources, in compliance with the Association for Assessment and Accreditation of Laboratory Animal Care regulations, approved all in vivo protocols, housing, and anesthesia. Female C57BL/6 mice 6-8 weeks of age (17-22 g) were obtained from Charles River Laboratories (Hollister, CA). They were administered with 5 mCi of the radioiodinated antibodies via IV bolus. At 1, 4, 24, and 48 hr postdose, blood (processed for plasma), brain, liver, lungs, spleen, bone marrow, and muscle (gastrocnemius) were collected (n = 3/antibody) and stored frozen until analyzed for total radioactivity on a gamma counter (2480 Wizard 2 Automatic Gamma Counter, PerkinElmer, Waltham, MA). The radioactivity level in each sample was calculated and expressed as percentage of Injected Dose per gram or milliliter of sample (% ID/g or % ID/mL). The % ID/g-time data were plotted using GraphPad Prism (Version 6.05) and the area under the concentration time curve (AUC) was determined. The standard deviations (SD) for the AUC estimates were calculated using the method described by Bailer (Bailer, 1988) .
Immunostaining
Wild-type mice were IV injected with 5 mg/kg of antibody followed by PBS perfusion 1 hr postdose. Brains were drop fixed in 4% paraformaldehyde (PFA) overnight at 4 C, followed by 30% sucrose overnight at 4 C. Brain tissue was sectioned at 35 mm thickness on a sliding microtome, blocked for 1-3 hr in 5% BSA 0.3% Triton, incubated with 1:500 Alexa Fluor 488 anti-human secondary antibody (Life Technologies) in 1% BSA 0.3% Triton for 2 hr at RT. Mounted slides were subsequently analyzed by Leica fluorescence microscopy.
Measuring Antibody Concentrations and Mouse Ab x-40 in Brain and Plasma All mice used in therapeutic dosing studies were female C57BL/6 wildtype mice, ages 6-8 weeks. Mice were intravenously injected with antibody and taken down at the indicated times postinjection. Prior to perfusion with PBS, whole blood was collected in plasma microtainer tubes (BD Diagnostics) and spun down at 14,000 rpm for 2 min. Plasma supernatant was isolated for antibody and mouse Ab x-40 measurements where appropriate. Brains were extracted and tissues were homogenized in 1% NP-40 (Cal-Biochem) in PBS containing Complete Mini EDTA-free protease inhibitor cocktail tablets (Roche Diagnostics). Homogenized brain samples were rotated at 4 C for 1 hr before spinning at 14,000 rpm for 20 min. Supernatant was isolated for brain antibody measurement. For PK/PD studies, one hemibrain was isolated for Ab x-40 measurements and homogenized in 5M guanidine hydrochloride buffer. Samples rotated for 3 hr at RT prior to diluting (1:10) in 0.25% casein, 5 mM EDTA (pH 8.0), in PBS containing freshly added aprotinin (20 mg/ml) and leupeptin (10 mg/ml). Diluted homogenates were spun at 14,000 rpm for 20 min, and supernatants were isolated for mouse Ab x-40 measurements.
PK Assays
Antibody concentrations in mouse serum, and brain samples were measured using an ELISA. NUNC 384 well Maxisorp immunoplates (Neptune, NJ) were coated with F(ab') 2 fragment of donkey anti-human IgG, Fc fragment-specific polyclonal antibody (Jackson ImmunoResearch, West Grove, PA). After blocking the plates, each antibody was used as a standard to quantify the respective antibody concentrations. Standards and samples were incubated on plates for 2 hr at RT with mild agitation. Bound antibody was detected with HRP-conjugated F(ab') 2 goat anti-human IgG, Fc specific polyclonal antibody (Jackson ImmunoResearch). Concentrations were determined from the standard curve using a four-parameter nonlinear regression program. The assay had lower limit of quantitation values of 3.12 ng/ml in serum and 1.56 ng/ml in brain. For anti-CD98hc brain samples, antibody concentrations in mouse serum and brain samples were measured using an ELISA on the GYROS platform (Gyros Ab, Sweden) due to strong matrix interference specific to these antibodies. The Gyros assay uses the same antibody pairs as the plate format. The assay had lower limit of quantitation (LLOQ) values of 5 ng/ml in serum and brain. PD Assays Ab x-40 concentrations in plasma and brain samples were measured using an ELISA similar to methods for PK analysis above. Briefly, rabbit polyclonal antibody specific for the C terminus of Ab 40 (Millipore, Bedford, MA) was coated onto plates, and biotinylated anti-mouse Ab monoclonal antibody M3.2 (Covance, Dedham, MA) was used for detection. The assay had LLOQ values of 1.96 pg/ml in plasma and 39.1 pg/g in brain.
Primary Mouse Brain Endothelial Cell Isolation and Mass Spectrometry Brain endothelial cells (BEC; CD31+/CD45À) were isolated by flow cytometry from 40 adult female C57BL/6 mice (6-8 weeks of age). A negatively sorted population (CD31À/CD45À) was collected in parallel for comparison. In total, approximately 5 3 10 5 cells were sorted to acquire a BEC population with a purity of $92%. Isolated BECs and the negatively selected control cells were lysed in RIPA buffer in the presence of protease inhibitors and separated by SDS-PAGE on a 4%-12% Bis-Tris gel. Of the BEC lysate, 10% was used for a silver stained gel, 10% for a western blot against transferrin receptor (TfR) and the remainder loaded in a single lane and stained with Simply Blue Coomassie. In parallel lanes adjacent to the BEC lysate, lysates stemming from $5,000, $5,000, and $40,000 CD31À/CD45À cells from the negatively selected population were run for silver staining, anti-TfR western, and Coomassie staining, respectively. For mass spectrometry analysis, the Coomassie-stained gel lane corresponding to the BEC lysate (CD31+/CD45À) and the negative control (CD31À/CD45À) lysates were each cut into 15 sections from top to bottom. Each gel lane was subjected to in gel trypsin digestion using standard methods, as previously described (Zhang et al., 2011) . Gel slices were diced into 1 mm cubes and destained by serial washes with 103 gel volumes of 50 mM ammonium bicarbonate, 50% acetonitrile (pH 8.0), then 103 gel volumes 100% acetonitrile for 15 min each. In-gel reduction and alkylation were performed with 25 mM dithiothreitol/100 mM ammonium bicarbonate (30 min, 50 C), and 50 mM iodoacetamide/100 mM ammonium bicarbonate (20 min, RT in the dark), respectively. Gel pieces were subsequently washed and dehydrated with an additional 103 gel volumes of 100% acetonitrile. Trypsin solution was prepared at a concentration of 10 ng/mL trypsin in 50 mM ammonium bicarbonate (pH 8.0) with 5% acetonitrile and added to the gel pieces on ice. Gel pieces were soaked in trypsin solution for 1 hr on ice and in-gel digestion performed overnight at 37 C. Digested peptides were collected and gel pieces extracted an additional time with 50% acetonitrile/5% formic acid. Samples were dried to completion in a SpeedVac and resuspended in 3% acetonitrile/5% formic acid for analysis. For mass spectrometry analysis, peptides were injected onto a 0.1 mm 3 100 cm C18 column packed with 1.7 mm BEH-130 resin (Waters, Milford MA) at a flow rate of 1.5 ml/min for 10 min using a NanoAcquity UPLC. Peptides were separated using a two-stage linear gradient where solvent B (98% acetonitrile/2% water/0.1% formic acid) ramped from 5% to 25% over 20 min and then from 25% to 50% over 2 min. Buffer A was comprised of (98% water/ 2% acetonitrile/0.1% formic acid). Peptides were introduced to an Orbitrap Velos (ThermoFisher Scientific, San Jose, CA) mass spectrometer using the ADVANCE Captive Spray Ionization source (Microm-Bruker, Auburn, CA). Orbitrap full-MS (MS1) spectra were collected at 60,000 resolution and used to trigger data dependent MS2 scans in the linear ion trap on the top eight most intense ions. MS2 spectra were searched using Mascot against a concatenated target-decoy database of mouse proteins from UniProt. Peptide spectral matches were sequentially filtered to 5% peptide false discovery rate (pepFDR) using a linear discriminant analysis, and subsequently to a 2% protein false discovery rate (final pepFDR < 0.5%). Area under curve (AUC) represents the average of two technical replicates for the integrated intensity of the top three most abundant peptide hits as previously described (Ahrné et al., 2013) .
Immunocytochemistry IMCD3 cells stably overexpressing mouse CD98hc were plated in 384-well optical plates (Perkin Elmer) and grown for 1-2 days after confluence. Cells were treated for 1 hr at 1 mM with anti-CD98hc bispecifics, washed with PBS, fixed with 4% PFA/4% sucrose/PBS for 5-10 min at RT, followed by ice cold 100% methanol fixation for 20 min. Cells were blocked with 1% donkey serum, 2% BSA, 0.1% Triton X-100 in PBS for 30 min RT. Primary antibodies used were mouse anti-Lamp1 (BD, 1:200) and goat anti-CD98hc (Santa Cruz 1:200), diluted in block, and incubated overnight at 4 C. The following secondary antibodies were used: donkey anti-human IgG Alexa 405, donkey anti-goat Cy3, and donkey anti-rabbit Alexa 647 (Jackson Immunoresearch).
Image Acquisition and Colocalization Analysis
Images were taken on a Phoenix high content system with a 403 NA1.1 water lens in confocal mode. Laser lines 375, 488, 550, and 640 were used. Four images per well were taken and 150-200 cells in each image. Five wells per condition were imaged, thus more than 3,000 cells are analyzed per treatment. Images were transferred into ImageXpress 5.1 for analysis. For each individual channel to be analyzed, the background was removed using the TopHat function, and then the ''adapted threshold'' function was used to create stained object masks over the original channel image for analysis. To quantify only stained intracellular puncta, CD98hc membrane staining was excluded from analysis based on size. Total number of CD98hc puncta was quantified from the entire image consisting of about 150-200 cells. To identify internalized CD98hc staining colocalized with Lamp1, the ''keep marked object'' function was used to identify overlapping objects from two different channels. Total number of colocalized CD98hc puncta was quantified from the entire image and sums of each well were reported by the program and exported to Excel. Percent CD98hc puncta colocalized is calculated as number of colocalized CD98hc puncta with Lamp1 divided by the total number of total CD98hc puncta. Averages from 5 wells were calculated and graphed in Prism.
Amino Acid Uptake Assay IMCD3 cells stably overexpressing CD98hc were plated in 384-well plates (Perkin Elmer) the day before. Antibodies were added to cells the next morning and incubated for 24 hr at 1 mM in growth media. Four wells per condition were used and the experiment was repeated 3 times. After 24 hr, cells were equilibrated for 30 min at 37 C with Met-Free DMEM. To measure amino acid uptake by the cell, the amino acid methionine analog, homopropargylglycine (HPG, Life Technolgies C10186), was added to the cells at 50 mM final concentration. A total of 10 mM BCH (Sigma) was used as positive control and was added the same time as HPG. After 30 min incubation at 37 C, additional growth media was added for another 30 min. Cells were then washed with PBS and lysed in RIPA buffer with Complete protease inhibitors (Roche). All liquid handling was done with a Bravo automation system using a 384 tip head. Cell lysates were transferred to 384-well plates and incubated at 4 C overnight. The transported methionine was detected by biotinylation via the click tag on HPG. Plates were washed three times, and click reaction was performed according to manufacturer instructions (Life Technologies B10184). The total amount of biotinylated methionine was detected using ECL. Results were plotted in GraphPad Prism.
Western Blot Analysis Mouse brain tissues were isolated after PBS perfusion and homogenized in 1% NP-40 with protease inhibitors as described above (see ''Measuring Antibody Concentrations and Mouse Ab x-40 in Brain and Plasma''). Approximately 20 ug of protein was loaded onto 4%-12% Bis-Tris Novex gels (Life Technologies). Gels were transferred onto nitrocellulose membranes using the iBlot system (Life Technologies), and western blotting was performed using Odyssey blocking buffer reagents and secondary antibodies (LICOR). Mouse crossreactive goat anti-CD98hc (Santa Cruz, M-20, 1:200) was used to detect CD98hc in brain lysates. Rabbit anti-bactin (Abcam8227, 1:2000) served as a loading control. Western membranes were imaged and quantified using manufacturer supplied software and system (Odyssey/LICOR). Wild-type IMCD3 cells were plated in 48-well plates overnight, incubated with antibodies for 24 hr, washed with PBS, and then lysed with RIPA buffer supplemented with Complete protease inhibitors (Roche). Three wells per condition were used and the experiment was repeated three times. Lysates were probed for CD98hc with goat anti-CD98hc (Santa Cruz) and actin (Abcam) by western blot as described above.
Statistical Analysis
All values are expressed as mean ± SEM, unless otherwise indicated, and p values were assessed by ordinary one-way or two-way ANOVA, with Dunnett multiple comparisons test using Graphpad Prism Version 6. 
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